{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/a99d383c-8d83-4c72-94e3-3da1b572fad7/PDF","dcterms:extent":"161 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/3db532a1-1815-49f5-8258-5779a83dccee/TEXT","dcterms:extent":"23 KB"}],"edm:TimeSpan":{"@rdf:about":"2022-2025","edm:begin":{"@xml:lang":"en","#text":"2022"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-RJNKITXS","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q"},{"@xml:lang":"sl","#text":"Placebo"}],"dcterms:issued":"2025","dc:creator":["Lešnik, Kaja","Slomšek, Ana"],"dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"str. 55-58"}],"dc:identifier":["COBISSID_HOST:248525059","ISSN:2820-5014","URN:URN:NBN:SI:doc-RJNKITXS"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Fakulteta za farmacijo, ŠSSFD"},"dc:subject":[{"@xml:lang":"en","#text":"acne"},{"@xml:lang":"sl","#text":"akne"},{"@xml:lang":"en","#text":"biological drugs"},{"@xml:lang":"en","#text":"biological molecule inhibitors"},{"@xml:lang":"sl","#text":"Biološka zdravila"},{"@xml:lang":"en","#text":"genetic engineering"},{"@xml:lang":"sl","#text":"Genska terapija"},{"@xml:lang":"sl","#text":"gensko inženirstvo"},{"@xml:lang":"sl","#text":"matične celice"},{"@xml:lang":"en","#text":"multifactorial pathophysiology"},{"@xml:lang":"en","#text":"stem cell therapy"},{"@xml:lang":"sl","#text":"večfaktorska patofiziologija"},{"@xml:lang":"sl","#text":"zaviralci bioloških molekul"}],"dcterms:temporal":{"@rdf:resource":"2022-2025"},"dc:title":{"@xml:lang":"sl","#text":"Biološka zdravila za zdravljenje hormonalnih aken| različni pristopi zdravljenja dermatoveneroloških bolezni|"},"dc:description":[{"@xml:lang":"sl","#text":"Acne is, especially among adolescents and young adults, a widespread dermatological condition with a multifactorial pathogenesis. The desire for more effective therapeutic outcomes with fewer side effects is driving improvements in existing treatment approaches, as well as the development of entirely new ones. The development of modern biological and biotechnological therapies is based on a thorough understanding of disease pathogenesis, which enables action on specific therapeutic targets. Antibodies that inhibit certain acne-related factors such as certain cytokines and enzymes are commonly used, but most of these biological drugs are off-label, meaning they are not registered for this indication. The potential of using genetic engineering for the purpose of delivering the active substance to the site of inflammation and stem cells to limit the inflammatory response is also being explored"},{"@xml:lang":"sl","#text":"Akne so predvsem pri mladostnikih in mladih odraslih pogosto dermatološko stanje z izrazito večfaktorsko patofiziologijo. Želja po učinkovitejših terapijah z manj neželenih učinkov spodbuja izboljšanje dosedanjih in vodi v razvoj novih terapevtskih pristopov. Razvoj sodobnih bioloških zdravil je osnovan na dobrem poznavanju mehanizmov nastanka bolezni, kar omogoča njihovo usmerjeno delovanje na specifične terapevtske tarče. Pogosta je uporaba protiteles, ki zavirajo določene dejavnike, povezane z razvojem aken, kot so nekateri citokini in encimi, vendar je njihova uporaba večinoma nenamenska, torej niso registrirana za to indikacijo. Raziskuje se tudi potencial uporabe genskega inženiringa za namene dostave zdravilne učinkovine na mesto vnetja in matičnih celic za omejitev vnetnega odziva"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-RJNKITXS","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-RJNKITXS"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/a99d383c-8d83-4c72-94e3-3da1b572fad7/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:dataProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-RJNKITXS/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-RJNKITXS"}}}}